Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: an Updated Systematic Review and Meta-analysis

Overview

Journal Pituitary

Specialty Endocrinology

Date 2024 Dec 26

PMID 39724512

Authors

Mylena Maria Guedes de Almeida

Pedro Henrique Aquino Gil de Freitas

Aurea Maria Salomao Simao

Ana Beatriz Bertol

Barkha Vijendra

Bianca Lisa de Faria

Affiliations

Soon will be listed here.

Abstract

Purpose: Craniopharyngiomas (CPs) often lead to growth hormone deficiency (GHD) in children. Growth hormone replacement therapy (GHRT) is essential for managing GHD but its impact on body mass index (BMI) and metabolic outcomes is controversial. Concerns exist that GHRT might contribute to tumor recurrence, with guidelines varying on when to start therapy post-surgery. This updated systematic review and meta-analysis explores the effects and timing of GHRT in children post-craniopharyngioma surgery.

Methods: We systematically searched PubMed, Embase, and Cochrane Library databases. Included studies compared the effects of GHRT in childhood-onset craniopharyngioma patients who received GHRT versus those who did not. Random-effects meta-analyses were used to pool relative risk (RR) or mean difference (MD) for each outcome. Heterogeneity was assessed using the I² statistic. This study is registered with PROSPERO (CRD42024498082).

Results: We included 11 studies in the meta-analysis. No differences in tumor progression/recurrence were found between the GHRT and no GHRT groups (RR 0.77, 95% CI 0.56-1.05, p = 0.10). The impact of timing of GHRT is less clear because of limited data and high heterogeneity. There were no differences in BMI between the GHRT and no GHRT (MD -0.94, 95% CI -1.88,0.00, p = 0.05). Two studies reported that GHRT might improve lipid profiles.

Conclusion: Our study suggests that GHRT does not increase the risk of tumor progression/recurrence in CP patients. GHRT can improve linear growth, but its effects on the BMI and lipid profiles remain inconclusive, requiring further studies.

References

Boguszewski M, Cardoso-Demartini A, Boguszewski C, Chemaitilly W, Higham C, Johannsson G . Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary. 2021; 24(5):810-827. PMC: 8416866. DOI: 10.1007/s11102-021-01173-0. View

Muller H, Merchant T, Warmuth-Metz M, Martinez-Barbera J, Puget S . Craniopharyngioma. Nat Rev Dis Primers. 2019; 5(1):75. DOI: 10.1038/s41572-019-0125-9. View

Zhou Z, Zhang S, Hu F . Endocrine Disorder in Patients With Craniopharyngioma. Front Neurol. 2021; 12:737743. PMC: 8675636. DOI: 10.3389/fneur.2021.737743. View

Wijnen M, Olsson D, van den Heuvel-Eibrink M, Hammarstrand C, Janssen J, van der Lely A . Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. Eur J Endocrinol. 2017; 178(1):93-102. DOI: 10.1530/EJE-17-0707. View

Geffner M, Lundberg M, Koltowska-Haggstrom M, Abs R, Verhelst J, Erfurth E . Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab. 2004; 89(11):5435-40. DOI: 10.1210/jc.2004-0667. View

Swerdlow A, Reddingius R, Higgins C, Spoudeas H, Phipps K, Qiao Z . Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab. 2001; 85(12):4444-9. DOI: 10.1210/jcem.85.12.7044. View

Sklar C, Antal Z, Chemaitilly W, Cohen L, Follin C, Meacham L . Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103(8):2761-2784. DOI: 10.1210/jc.2018-01175. View

Grimberg A, DiVall S, Polychronakos C, Allen D, Cohen L, Quintos J . Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016; 86(6):361-397. DOI: 10.1159/000452150. View

Wilson T, Rose S, Cohen P, Rogol A, Backeljauw P, Brown R . Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003; 143(4):415-21. DOI: 10.1067/s0022-3476(03)00246-4. View

10.

van Schaik J, Kormelink E, Kabak E, van Dalen E, Schouten-van Meeteren A, de Vos-Kerkhof E . Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study. Neuroendocrinology. 2023; 113(10):987-1007. DOI: 10.1159/000531226. View

11.

Alotaibi N, Noormohamed N, Cote D, Alharthi S, Doucette J, Zaidi H . Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis. World Neurosurg. 2017; 109:487-496.e1. PMC: 5729106. DOI: 10.1016/j.wneu.2017.09.164. View

12.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

13.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

14.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

15.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

16.

Shi J, Luo D, Weng H, Zeng X, Lin L, Chu H . Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020; 11(5):641-654. DOI: 10.1002/jrsm.1429. View

17.

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

18.

Boekhoff S, Bogusz A, Sterkenburg A, Eveslage M, Muller H . Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol. 2018; 179(5):331-341. DOI: 10.1530/EJE-18-0505. View

19.

Darendeliler F, Karagiannis G, Wilton P, Ranke M, Albertsson-Wikland K, Anthony Price D . Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr. 2006; 95(10):1284-90. DOI: 10.1080/08035250600577889. View

20.

Du H, Chen K, Zhang L, Zhang Y, Wu D, Guo X . Blood Lipid Disorders in Post-Operative Craniopharyngioma Children and Adolescents and the Improvement with Recombinant Human Growth Hormone Replacement. Diabetes Metab Syndr Obes. 2023; 16:3075-3084. PMC: 10559785. DOI: 10.2147/DMSO.S425399. View